Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.

Autor: Ha JT; Department of Renal Medicine, Wollongong Hospital, Wollongong, NSW, Australia.; Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales Medicine & Health, Sydney., Hiremath S; Division of Nephrology, Department of Medicine, University of Ottawa, Ottawa., Jun M; Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales Medicine & Health, Sydney., Green SC; Department of Medicine, University of Otago, Christchurch, Christchurch, New Zealand., Wheeler DC; Department of Renal Medicine, University College London, London., Coyne DW; Division of Nephrology, Washington University School of Medicine, St. Louis., Perkovic V; Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales Medicine & Health, Sydney., Badve SV; Renal and Metabolic Division, The George Institute for Global Health, University of New South Wales Medicine & Health, Sydney.; Department of Renal Medicine, St. George Hospital, Sydney.

Publikováno v: NEJM evidence [NEJM Evid] 2024 Sep; Vol. 3 (9), pp. EVIDoa2300189. Date of Electronic Publication: 2024 Aug 26.

Discovery of DS44470011: An oral hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of renal anemia.

Autor: Fukuda T; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan. Electronic address: fukuda.takeshi.zv@daiichisankyo.co.jp., Kuribayashi T; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan., Takano R; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan., Sasaki K; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan., Tsuji T; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan., Niitsu Y; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan., Ishii K; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan., Hashimoto M; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan., Baba D; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan., Ito S; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan., Tanaka N; R&D Division, Daiichi Sankyo Co., Ltd., 1-2-58 Hiromachi, Shinagawa-ku, Tokyo 140-8710, Japan.

Publikováno v: Bioorganic & medicinal chemistry letters [Bioorg Med Chem Lett] 2024 Aug 01; Vol. 108, pp. 129799. Date of Electronic Publication: 2024 May 15.

The selective prolyl hydroxylase inhibitor IOX5 stabilizes HIF-1α and compromises development and progression of acute myeloid leukemia.

Autor: Lawson H; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Holt-Martyn JP; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Dembitz V; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Department of Physiology and Immunology and Croatian Institute for Brain Research, University of Zagreb School of Medicine, Zagreb, Croatia., Kabayama Y; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK., Wang LM; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Bellani A; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Atwal S; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Saffoon N; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Durko J; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., van de Lagemaat LN; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK.; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK., De Pace AL; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK., Tumber A; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Corner T; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Salah E; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Arndt C; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Brewitz L; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Bowen M; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK., Dubusse L; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., George D; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Allen L; The Institute of Cancer Research, London, UK.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., Guitart AV; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK.; Université de Bordeaux, Institut National de la Santé et de la Recherche Médicale INSERM U1035, Bordeaux, France., Fung TK; Leukemia and Stem Cell Biology Group, Comprehensive Cancer Centre, King's College London, London, UK.; Department of Haematological Medicine, King's College Hospital, King's College London, London, UK., So CWE; Leukemia and Stem Cell Biology Group, Comprehensive Cancer Centre, King's College London, London, UK.; Department of Haematological Medicine, King's College Hospital, King's College London, London, UK., Schwaller J; University Children's Hospital Basel (UKBB), Department of Biomedicine, University of Basel, Basel, Switzerland., Gallipoli P; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK., O'Carroll D; Centre for Regenerative Medicine, University of Edinburgh, Edinburgh, UK., Schofield CJ; Chemistry Research Laboratory, Department of Chemistry and the Ineos Oxford Institute for Antimicrobial Research, University of Oxford, Oxford, UK. christopher.schofield@chem.ox.ac.uk., Kranc KR; The Institute of Cancer Research, London, UK. kamil.kranc@icr.ac.uk.; Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, London, UK. kamil.kranc@icr.ac.uk.

Publikováno v: Nature cancer [Nat Cancer] 2024 Jun; Vol. 5 (6), pp. 916-937. Date of Electronic Publication: 2024 Apr 18.

The drug-specific properties of hypoxia-inducible factor-prolyl hydroxylase inhibitors in mice reveal a significant contribution of the kidney compared to the liver to erythropoietin induction.

Autor: Nakai T; Applied Oxygen Physiology Project, New Industry Creation Hatchery Center, Tohoku University, Seiryo-machi 2-1, Aoba-ku, Sendai, Miyagi 980-8575, Japan; Division of Oxygen Biology, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Aoba-ku, Sendai, Miyagi 980-8575, Japan., Saigusa D; Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University, Kaga 2-11-1, Itabashi-ku, Tokyo 173-8605, Japan., Kato K; Applied Oxygen Physiology Project, New Industry Creation Hatchery Center, Tohoku University, Seiryo-machi 2-1, Aoba-ku, Sendai, Miyagi 980-8575, Japan; Division of Oxygen Biology, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Aoba-ku, Sendai, Miyagi 980-8575, Japan., Fukuuchi T; Laboratory of Biomedical and Analytical Sciences, Faculty of Pharma-Science, Teikyo University, Kaga 2-11-1, Itabashi-ku, Tokyo 173-8605, Japan., Koshiba S; Department of Integrative Genomics, Tohoku Medical Megabank Organization, Tohoku University, Seiryo-machi 2-1, Aoba-ku, Sendai, Miyagi 980-8575, Japan; The Advanced Research Center for Innovations in Next-Generation Medicine, Tohoku University, 2-1, Seiryo-machi, Aoba-ku, Sendai 980-8573, Japan., Yamamoto M; Department of Biochemistry and Molecular Biology, Tohoku Medical Megabank Organization, Tohoku University, Seiryo-machi 2-1, Aoba-ku, Sendai, Miyagi 980-8575, Japan., Suzuki N; Applied Oxygen Physiology Project, New Industry Creation Hatchery Center, Tohoku University, Seiryo-machi 2-1, Aoba-ku, Sendai, Miyagi 980-8575, Japan; Division of Oxygen Biology, Tohoku University Graduate School of Medicine, Seiryo-machi 2-1, Aoba-ku, Sendai, Miyagi 980-8575, Japan. Electronic address: norio.suzuki.c8@tohoku.ac.jp.

Publikováno v: Life sciences [Life Sci] 2024 Jun 01; Vol. 346, pp. 122641. Date of Electronic Publication: 2024 Apr 15.

Prolyl hydroxylase inhibitor FG-4592 alleviates neuroinflammation via HIF-1/BNIP3 signaling in microglia.

Autor: Ruan Q; Beijing Institute of Basic Medical Sciences, Beijing 100850, China; State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu 211198, China; Research Center for Biochemistry and Molecular Biology, Xuzhou Medical University, Xuzhou, Jiangsu 221004, China., Geng Y; Beijing Institute of Basic Medical Sciences, Beijing 100850, China., Zhao M; Beijing Institute of Basic Medical Sciences, Beijing 100850, China., Zhang H; Beijing Institute of Basic Medical Sciences, Beijing 100850, China., Cheng X; Beijing Institute of Basic Medical Sciences, Beijing 100850, China., Zhao T; Beijing Institute of Basic Medical Sciences, Beijing 100850, China., Yue X; Beijing Institute of Basic Medical Sciences, Beijing 100850, China., Jiang X; Beijing Institute of Basic Medical Sciences, Beijing 100850, China., Jiang X; Beijing Institute of Basic Medical Sciences, Beijing 100850, China., Hou XY; State Key Laboratory of Natural Medicines, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu 211198, China. Electronic address: xyhou@cpu.edu.cn., Zhu LL; Beijing Institute of Basic Medical Sciences, Beijing 100850, China; Co-Innovation Center of Neuroregeneration, Nantong University, Nantong 226019, China. Electronic address: linglingzhuamms@126.com.

Publikováno v: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie [Biomed Pharmacother] 2024 Apr; Vol. 173, pp. 116342. Date of Electronic Publication: 2024 Mar 01.